Tomas Philipson

Names

Contact

Affiliations

• University of Chicago → Harris School of Public Policy
  • website
  • location: Chicago, Illinois (United States)
• National Bureau of Economic Research (NBER)
  • website
  • location: Cambridge, Massachusetts (United States)
• Manhattan Institute
  • website
  • location: New York, New York (United States)
• American Enterprise Institute
  • website
  • location: Washington, District of Columbia (United States)

Research profile

author of:

• Antitrust and the Not-For-Profit Sector
  by Tomas J. Philipson & Richard A. Posner
• Merit Motives and Government Intervention: Public Finance in Reverse
  by Casey B. Mulligan & Tomas J. Philipson
• The Economic Epidemiology of Crime.
  by Philipson, Tomas J. & Posner, Richard A.
• Equilibrium and Efficiency in an Organized Vote Market.
  by Philipson, Tomas J. & Snyder, James M., Jr
• The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry
  by Frank R. Lichtenberg & Tomas J. Philipson
• Self-Interested Treatment Evaluation in Experiments
  by Tomas J. Philipson
• External Treatment Effects and Program Implementation Bias
  by Tomas J. Philipson
• The Long-Run Growth in Obesity as a Function of Technological Change
  by Tomas J. Philipson & Richard A. Posner
• Managed Care and the Quality of Health Care: A Misguided Debate?
  by Philipson, Thomas
• Longevity Complementarities under Competing Risks
  by Tomas J. Philipson & William H. Dow & Xavier Sala-i-Martin
• Surplus Appropriation from R&D and Health Care Technology Assessment Procedures
  by Tomas J. Philipson & Anupam B. Jena
• Pricing and R&D When Consumption Affects Longevity
  by Pierre-Yves Geoffard & Tomas Philipson
• Economic epidemiology and infectious diseases
  by Philipson, Tomas
  edited by
• Intellectual Property and Marketing
  by Darius Lakdawalla & Tomas Philipson & Y. Richard Wang
• The Future of Old-Age Longevity: Competitive Pricing of Mortality Contingent Claims
  by Charles Mullin & Tomas Philipson
• Welfare-Enhancing Technological Change and the Growth of Obesity
  by Darius Lakdawalla & Tomas Philipson & Jay Bhattacharya
• Measurement errors: A principal investigator-agent approach
  by Philipson, Tomas & Malani, Anup
• Multiple-output agency incentives in data production: experimental evidence
  by Philipson, Tomas & Lawless, Thomas
• Economic Epidemiology and Infectious Diseases
  by Tomas Philipson
• Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS
  by Avner Ahituv & V. Joseph Hotz & Tomas Philipson
• Observational Agency and Supply-Side Econometrics
  by Tomas Philipson
• Subject Evaluation in Social Experiments
  by Tomas Philipson & Larry V. Hedges
• Health Care, Technological Change, and Altruistic Consumption Externalities
  by Tomas Philipson & Stephane Mechoulan & Anupam Jena
• Surplus Appropriation from R&D and Health Care Technology Assessment Procedures
  by Tomas J. Philipson & Anupam B. Jena
• Death, tetanus, and aerobics: The evaluation of disease-specific health interventions
  by William H. Dow & Jessica Holmes & Tomas Philipson & Xavier Sala-i-Martin
• Rational Epidemics and their Public Control.
  by Geoffard, P. Y. & Philipson, T.
• The nonprofit sector and industry performance
  by Lakdawalla, Darius & Philipson, Tomas
• An Empirical Examination of Information Barriers to Trade inInsurance
  by John Cawley & Tomas Philipson
• The Rise in Old Age Longevity and the Market for Long-Term Care
  by Thomas Philipson & Darius Lakdawalla
• Social Welfare and Measurement of Segregation
  by Philipson Tomas
• Data Markets, Missing Data, and Incentive Pay.
  by Philipson, Tomas
• Pricing and R&D with Related Margins
  by Geoffard, P. Y. & Philipson, T.
• An empirical examination of the implications of assortative matching on the incidence of HIV
  by Dow, William H. & Philipson, Tomas
• Public Spending on AIDS Education: An Economic Analysis.
  by Philipson, Tomas & Posner, Richard A.
• Is Health Care Technology Over-Approved? A Meta-Analysis of Revealed Preference
  by Larry V. Hedges & Tomas Philipson
• The evaluation of new health care technology: The labor economics of statistics
  by Philipson, Tomas
• Rational Epidemics and Their Public Control.
  by Geoffard, Pierre-Yves & Philipson, Tomas
• Disease Complementarities and the Evaluation of Public Health Interventions
  by William H. Dow & Jessica Holmes & Tomas Philipson & Xavier Sala-i-Martin
• The Quantity and Quality of Life and the Evolution of World Inequality
  by Gary S. Becker & Tomas J. Philipson & Rodrigo R. Soares
• Old-Age Longevity and Mortality-Contingent Claims
  by Tomas J. Philipson & Gary S. Becker
• Mortality Contingent Claims, Health Care, and Social Insurance
  by Tomas Philipson & Gary S. Becker
• Merit Motives and Government Intervention: Public Finance in Reverse
  by Casey Mulligan & Tomas Philipson
• Nonprofit Production.
  by Tomas Philipson & Darius Lakdawalla
• Estimating the Extent of Trade Under Incomplete Information: The Case of HIV
  by Tomas Philipson & Edward Vytlacil
• The Private Demand for Information and the Effects of Public Testing Programs: The Case of HIV.
  by Boozer, M. & Philipson, T.
• The Future of Old-Age Longevity: Competitive Pricing of Morality Contingent Claims
  by Charles Mullin & Tomas Philipson
• Disease Eradication: Private versus Public Vaccination.
  by Geoffard, Pierre-Yves & Philipson, Tomas
• Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs
  by Tomas J. Philipson & Anupam B. Jena
• Nonprofit Production and Competition
  by Darius Lakdawalla & Tomas Philipson
• Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
  by Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck
• An Empirical Examination of Information Barriers to Trade in Insurance
  by Tomas Philipson & John Cawley
• Data MArkets and OPtimal Sample Size Determination
  by Geoffard, P. Y. & Philipson, T.
• Aging and the Growth of Long-Term Care
  by Darius Lakdawalla & Tomas Philipson
• The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination
  by Darius Lakdawalla & Tomas Philipson
• Health investment complementarities under competing risks
  by William H. Dow & Tomas Philipson & Xavier Sala-i-Martin & Jessica Holmes
• An Empirical Examination of Information Barriers to Trade in Insurance
  by John Cawley & Tomas Philipson
• Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts
  by Tomas J. Philipson & Ernst R. Berndt & Adrian H. B. Gottschalk & Matthew W. Strobeck
• Antitrust in the Not-For-Profit Sector
  by Tomas J. Philipson & Richard A. Posner
• Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets
  by Tomas Philipson & Stephane Mechoulan
• Disease Eradication: Private vs. Public Vaccination.
  by Geoffard, P. Y. & Philipson, T.
• The welfare loss of disease and the theory of taxation
  by Philipson, Tomas
• The Quantity and Quality of Life and the Evolution of World Inequality
  by Gary S. Becker & Tomas J. Philipson & Rodrigo R. Soares
• Consumption vs. Production of Insurance
  by Tomas Philipson & George Zanjani
• The Rise in Old Age Longevity and the Market for Long-Term Care
  by Darius Lakdawalla & Tomas Philipson
• Death, Tetanus and Aerobics: The Evaluation of Disease-Specific Health Interventions
  by Holmes, Jessica & Philipson, Tomas & Sala-i-Martin, Xavier & Tahvonen, Olli
• Mortality Contingent Claims, Health Care, and Social Insurance
  by Tomas Philipson & Gary S. Becker
• The Value of Life Near its End and Terminal Care
  by Gary Becker & Kevin Murphy & Tomas Philipson
• Is the Food and Drug Administration Safe and Effective?
  by Tomas J. Philipson & Eric Sun
• Is the Obesity Epidemic a Public Health Problem? A Decade of Research on the Economics of Obesity
  by Tomas Philipson & Richard Posner
• Integrated Insurance Design in the Presence of Multiple Medical Technologies
  by Dana Goldman & Tomas Philipson
• The Value of Life in General Equilibrium
  by Anupam Jena & Casey Mulligan & Tomas J. Philipson & Eric Sun
• Medical Care Output and Productivity in the Nonprofit Sector
  by Tomas Philipson & Darius Lakdawalla
  edited by
• Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
  by Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson
  edited by
• Asymmetric Information and the Not-for-Profit Sector Does Its Output Sell a a Premium?
  by Tomas Philipson
  edited by
• Theories of Firm Behavior in the Nonprofit Sector. A Synthesis and Empirical Evaluation
  by Anup Malani & Tomas Philipson & Guy David
  edited by
• Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption
  by Anupam Jena & Tomas Philipson
• Is the Food And Drug Administration Safe And Effective?
  by Tomas J. Philipson & Eric Sun
• The Rise in Old-Age Longevity and the Market for Long-Term Care
  by Darius Lakdawalla & Tomas Philipson
• Aging and the Growth of Long-Term Care
  by Darius Lakdawalla & Tomas Philipson
• The institute of medicine report on the FDA: where is the science?
  by Tomas Philipson & Anupam B. Jena & Eric Sun
• The Value of Life Near its End and Terminal Care
  by Gary Becker & Kevin Murphy & Tomas Philipson
• Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS
  by Avner Ahituv & V. Joseph Hotz & Tomas Philipson
• The Long-Run Growth in Obesity as a Function of Technological Change
  by Tomas J. Philipson & Richard A. Posner
• Labor Supply and Weight
  by Darius Lakdawalla & Tomas Philipson
• Integrated Insurance Design in the Presence of Multiple Medical Technologies
  by Tomas J. Philipson & Dana Goldman
• Is the Obesity Epidemic a Public Health Problem? A Review of Zoltan J. Acs and Alan Lyles's Obesity, Business and Public Policy
  by Tomas J. Philipson & Richard A. Posner
• Public Financing and the Market for Long-Term Care
  by Darius Lakdawalla & Thomas Philipson
  edited by
• The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination
  by Darius Lakdawalla & Tomas Philipson
• The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US
  by Frank R. Lichtenberg & Tomas J. Philipson
• Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts
  by Philipson, Tomas & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Sun, Eric
• Dynamic information release
  by Tomas Philipson
• External Treatment Effects and Program Implementation Bias
  by Tomas Philipson
• Cost-effectiveness analysis and innovation
  by Jena, Anupam B. & Philipson, Tomas J.
• Antitrust in the Not-for-Profit Sector
  by Tomas J. Philipson & Richard A. Posner
• The world‐wide growth in obesity: an economic research agenda
  by Tomas Philipson
• An Economic Evaluation of the War on Cancer
  by Eric C. Sun & Anupam B. Jena & Darius N. Lakdawalla & Carolina M. Reyes & Tomas J. Philipson & Dana P. Goldman
• The Effects of Product Liability Exemption in the Presence of the FDA
  by Tomas J. Philipson & Eric C. Sun & Dana Goldman
• The Impact of Comparative Effectiveness Research on Health and Health Care Spending
  by Anirban Basu & Tomas J. Philipson
• Terminal Care and The Value of Life Near Its End
  by Tomas J. Philipson & Gary Becker & Dana Goldman & Kevin M. Murphy
• `Me-Too' Innovation in Pharmaceutical Markets
  by Jena Anupam B. & Calfee John E. & Mansley Edward C. & Philipson Tomas J.
• Public Financing and the Market for Long-Term Care
  by Lakdawalla Darius & Philipson Thomas
• Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
  by Berndt Ernst R. & Gottschalk Adrian H. B. & Philipson Tomas & Strobeck Matthew W.
• Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs
  by Philipson Tomas J. & Jena Anupam B.
• The Effects of Product Liability Exemption in the Presence of the FDA
  by Tomas J. Philipson & Eric Sun & Dana Goldman
  edited by
• "Me-Too" Innovation in Pharmaceutical Markets
  by Anupam B. Jena & John E. Calfee & Edward C. Mansley & Tomas J. Philipson
  edited by
• Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets
  by Anup Malani & Tomas J. Philipson
• Public Liabilities and Health Care Policy
  by Kristopher J. Hult & Tomas J. Philipson
• Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension
  by Tomas J. Philipson & George Zanjani
• Adjusting National Accounting for Health: Is the Business Cycle Countercyclical?
  by Mark L. Egan & Casey B. Mulligan & Tomas J. Philipson
• International Health Economics
  by Mark Egan & Tomas J. Philipson
• Financial Health Economics
  by Ralph Koijen & Tomas Philipson & Harald Uhlig
• Health Care Adherence and Personalized Medicine
  by Mark Egan & Tomas J. Philipson
• How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations
  by Kristopher J. Hult & Sonia Jaffe & Tomas J. Philipson
• Sharing R&D Risk in Healthcare via FDA Hedges
  by Adam Jørring & Andrew W. Lo & Tomas J. Philipson & Manita Singh & Richard T. Thakor
• The Economic Value and Pricing of Personalized Medicine
  by Tomas J. Philipson
  edited by